Tomohiro Ozaki
-
- Colorectal Cancer Treatments and Studies 5
- Cancer Immunotherapy and Biomarkers 4
- Lung Cancer Research Studies 3
- Pancreatic and Hepatic Oncology Research 2
-
- Lung Cancer Treatments and Mutations 11
- Lung Cancer Diagnosis and Treatment 4
- Gastric Cancer Management and Outcomes 3
-
- Tumors and Oncological Cases 2
Tomohiro Ozaki
19 papers receiving 185 citations
Peers
Comparison fields: 5 of 38
- Oncology 127
- Pulmonary and Respiratory Medicine 117
- Cancer Research 24
- Geriatrics and Gerontology 6
- Hepatology 12
Countries citing papers authored by Tomohiro Ozaki
This map shows the geographic impact of Tomohiro Ozaki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tomohiro Ozaki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tomohiro Ozaki more than expected).
Fields of papers citing papers by Tomohiro Ozaki
This network shows the impact of papers produced by Tomohiro Ozaki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tomohiro Ozaki. The network helps show where Tomohiro Ozaki may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Tomohiro Ozaki, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 5 | |
| 2 | 2022 | 1 | |
| 3 | 2022 | 7 | |
| 4 | 2022 | 6 | |
| 5 | 2022 | 1 | |
| 6 | 2021 | 10 | |
| 7 | 2020 | 16 | |
| 8 | 2020 | 47 | |
| 9 | 2020 | 3 | |
| 10 | 2019 | 8 | |
| 11 | 2017 | 2 | |
| 12 | Erlotinib is a well-tolerated alternate treatment for non-small cell lung cancer in cases of gefitinib-induced hepatotoxicity. | 2014 | 11 |
| 13 | 2011 | 2 | |
| 14 | 2009 | 20 | |
| 15 | 2009 | 16 | |
| 16 | 2007 | 20 | |
| 17 | 2007 | 2 | |
| 18 | Phase I study of combination therapy with S-1 and weekly docetaxel for advanced gastric cancer. | 2007 | 1 |
| 19 | 2006 | 10 |
About Tomohiro Ozaki
Tomohiro Ozaki is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine, having authored 19 papers that have together received 188 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (11 papers), Colorectal Cancer Treatments and Studies (5 papers), Cancer Immunotherapy and Biomarkers (4 papers), Lung Cancer Diagnosis and Treatment (4 papers), Lung Cancer Research Studies (3 papers), Gastric Cancer Management and Outcomes (3 papers), Pancreatic and Hepatic Oncology Research (2 papers) and Tumors and Oncological Cases (2 papers). The work is most often cited by research in Oncology (127 citations), Pulmonary and Respiratory Medicine (117 citations) and Cancer Research (24 citations). Tomohiro Ozaki has collaborated with scholars based in Japan and United States. Frequent co-authors include Kazuhiko Nakagawa, Isamu Okamoto, Masahiro Fukuoka, Kenji Tamura, Toshio Shimizu, Taroh Satoh, Koichi Azuma, Nobuyuki Yamamoto, Shogo Nomura and Yusaku Akashi. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.